

The Brazilian Journal of INFECTIOUS DISEASES

www.elsevier.com/locate/bjid



Brief communication

Methicillin-resistant Staphylococcus aureus isolated from an intensive care unit in Minas Gerais, Brazil, over a six-year period



Thiago C. Nascimento^a, Cláudio G. Diniz^a, Vânia L. Silva^a, Alessandra B. Ferreira-Machado^b, Marina O. Fajardo^a, Tamara Lopes R. de Oliveira^c, Dennis de C. Ferreira^{d,e}, Fernanda S. Cavalcante^f, Kátia R. Netto dos Santos^{c,*}

^a Universidade Federal de Juiz de Fora, Departamento de Parasitologia, Microbiologia e Imunologia, Juiz de Fora, MG, Brazil

^b Universidade Federal do Triângulo Mineiro, Departamento de Microbiologia, Imunologia e Parasitologia, Uberaba, MG, Brazil

^c Universidade Federal do Rio de Janeiro, Instituto de Microbiologia Paulo de Góes, Rio de Janeiro, RJ, Brazil

^d Universidade Veiga de Almeida, Rio de Janeiro, RJ, Brazil

^e Universidade Estácio de Sá, Rio de Janeiro, RJ, Brazil

^f Universidade Federal do Rio de Janeiro, Macaé, RJ, Brazil

ARTICLE INFO

Article history: Received 30 August 2017 Accepted 20 October 2017 Available online 21 November 2017

Keywords: Clonal complex MRSA PFGE lineages SCCmec

ABSTRACT

To characterize methicillin-resistant *Staphylococcus aureus* isolates from an intensive care unit of a tertiary-care teaching hospital, between 2005 and 2010. A total of 45 isolates were recovered from patients admitted to the intensive care unit in the study period. Resistance rates higher than 80% were found for clindamycin (100%), erythromycin (100%), levofloxacin (100%), azithromycin (97.7%), rifampin (88.8%), and gentamycin (86.6%). The SCCmec typing revealed that the isolates harbored the types III (66.7%), II (17.8%), IV (4.4%), and I (2.2%). Four (8.9%) isolates carried non-typeable cassettes. Most (66.7%) of the isolates were related to the Brazilian endemic clone from CC8/SCCmec III, which was prevalent (89.3%) between 2005 and 2007, while the USA100/CC5/SCCmec II lineage emerged in 2007 and was more frequent in the last few years. The study showed high rates of antimicrobial resistance among methicillin-resistant *S. aureus* isolates and the replacement of Brazilian clone, a well-established hospital lineage, by the USA100 in the late 2000s, at the intensive care unit under study.

© 2017 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/ by-nc-nd/4.0/).

Staphylococcus aureus is one of the main causes of healthcareassociated infections.¹ Methicillin-resistant S. aureus (MRSA) is a growing problem worldwide and is associated with significant morbidity, mortality and increased costs of treatments.^{2,3}

* Corresponding author.

E-mail address: santoskrn@micro.ufrj.br (K.R. Santos).

https://doi.org/10.1016/j.bjid.2017.10.004

The majority of MRSA isolates are found in intensive care units (ICUs).⁴ In Brazil, these rates have even reached 70%.⁵ Methicillin resistance is located in a staphylococcal cassette chromosome (SCC*mec*) and the most frequent types are II, III and IV.²

Recent studies have described the emergency of MRSA lineages in hospitals worldwide.^{6,7} In Brazil, although isolates related to the Brazilian endemic clone (BEC)/SCCmec III/CC8

^{1413-8670/© 2017} Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

have caused the majority of hospital-acquired staphylococcal infections in the past,⁸ during the last decade an increased occurrence of nosocomial infections due to isolates carrying the SCC*mec* IV and II have been described.^{9–11} The characterization of MRSA isolates from patients in ICUs has already been described by various authors.^{9,11} However, these studies only analyzed a few ICU isolates within a larger hospital collection, without highlighting the characterization of these isolates. This study investigated the phenotypic and molecular characteristics of a collection of MRSA clinical isolates from patients admitted to a Brazilian ICU over a six-year period.

The study was conducted at a tertiary-care teaching hospital affiliated to the Federal University of Juiz de Fora, Minas Gerais, Brazil. This is a 146-bed, six of them being ICU. The MRSA isolates were obtained from patients admitted to the ICU consecutively, between 2005 and 2010, from different sources, such as tracheal secretion (53.3%), blood (20%), catheter tip (13.4%), and others (13.3%). Bacterial identification and susceptibility to methicillin were determined at the hospital laboratory by the classical identification tests¹² and the cefoxitin (Oxoid, Basingstoke, UK) disk diffusion test,13 respectively. Minimum inhibitory concentration (MIC) was assessed for 11 drugs as recommended by the CLSI.¹³ Bacterial DNA was extracted as previously described¹⁴ and the determination of the SCCmec types was performed according to Milheiriço et al.¹⁵ All MRSA isolates were typed by PFGE⁸ and the clonality was determined according to Van Belkum et al.¹⁶ criteria using previously characterized control strains, such as: USA100/SCCmec II, USA400 and USA800/SCCmec IV⁹ and BEC/SCCmec III.⁸ One isolate representative of each PFGE profile was chosen for characterization of the clonal complex (CC).¹⁷ Statistical comparisons were performed by analysis of contingency tables using Fisher's exact test; level of significance was established at 5% (p < 0.05).

Out of 76 S. *aureus* recovered from patients admitted to the ICU, between January/2005 and November/2010, 45 (59.2%) MRSA isolates recovered from 45 patients were evaluated. Except for vancomycin and linezolid, whose MIC_{90} was 2.0 μ g/mL, high rates of resistance were found for seven of the 11 antimicrobials tested (Table 1). Among the 45 MRSA isolates, 30 (66.7%) harbored the SCCmec III, 8 (17.8%) the type II, 2 (4.4%) the type IV and 1 (2.2%) the type I. Four (8.9%) MRSA isolates were non typeable (NT). S. *aureus* isolates carrying SCCmec III were related to the BEC/clonal complex (CC) 8 (Table 2). All the eight isolates that carried the SCCmec II were related to the USA100/CC5 lineage. Two isolates carrying the SCCmec IV belonged to the lineages USA400/CC1 and USA800/CC5. The SCCmec I isolate was associated to USA500/CC5 and the other four MRSA isolates did not belong to any clonality previously described (Table 2).

Brazilian studies have evaluated the epidemiology of MRSA and the results indicate that several lineages initially restricted to other continents are emerging in Brazilian hospitals.^{9–11} This study aimed to analyze the phenotypic and molecular characteristics of a collection of MRSA isolates obtained exclusively from patients admitted to an ICU and verified the replacement and emergence of lineages in the period under investigation. Initially there was a high dissemination of BEC/CC8/SCCmec III isolates from 2005 to 2007, with a prevalence of this clone of 89.3% among the isolates. The USA100/CC5/SCCmec II lineage emerged in 2007 and was more frequent in 2009 and 2010, while sporadic lineages occurred in 2008.

The BEC, a well-established lineage in Brazilian hospitals, representing about 90% of the nosocomial MRSA isolates in the late 1990s⁸ has been replaced in recent decades by SCCmec IV and II carrying MRSA isolates.9-11 A study also conducted in an ICU from Minas Gerais evaluated 36 MRSA isolated in 2009 and found that 58.3% of isolates carried the SCCmec II.¹⁸ In Rio de Janeiro, a study performed by our group in two hospitals, between 2004 and 2007, showed that about 50% of MRSA isolates were related to the BEC/SCCmec III lineage, while about 35% of isolates carried the SCCmec II or IV.9 In another study conducted by our group in a teaching hospital, between 2005 and 2006, the majority of isolates carried the cassette type IV (49%) and BEC isolates accounted for 49% of them among 83 nasal MRSA isolates analyzed,¹¹ confirming the replacing of this lineage for others in the years 2000, as found in the present study.

Antimicrobial agent	Minimal Inhibitory Concentration (µg/mL)			No (%) of resistant
	MIC ₅₀	MIC ₉₀	Range	isolates
Azithromycin	>1024.0	>1024.0	0.5->1024.0	44 (97.7)
Chloramphenicol	32.0	64.0	4.0-128.0	29 (64.4)
Clindamycin	>1024.0	>1024.0	512.0->1024.0	45 (100)
Erythromycin	512.0	512.0	256.0-512.0	45 (100)
Gentamicin	128.0	1024.0	0.125->1024.0	39 (86.6)
Levofloxacin	4.0	16.0	2.0–32.0	45 (100)
Linezolid	2.0	2.0	1.0–2.0	0 (0)
Rifampin	2.0	256.0	0.0625->1024.0	40 (88.8)
Tetracycline	32.0	64.0	0.0625-128.0	31 (68.8)
Trimethoprim/sulfamethoxazole	32.0/608.0	128.0/2432.0	0.0625/2.3-1024.0/19,456.0	32 (71.1)
Vancomycin	1.0	2.0	0.5–2.0	0 (0)

Table 1 – Antimicrobial resistance of 45 MRSA isolates recovered from patients of an ICU at a Minas Gerais teaching hospital, between 2005 and 2010.

MIC₅₀, minimal inhibitory concentration that inhibits 50% of bacterial population; MIC₉₀, minimal inhibitory concentration that inhibits 90% of bacterial population.

Download English Version:

https://daneshyari.com/en/article/8736728

Download Persian Version:

https://daneshyari.com/article/8736728

Daneshyari.com